Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
Boundless Bio raised $100 Million 6 months ago. i.e. if it they have licenced SRA737 / CCT-245737 then they clearly have the ability to raise funds to progress drug candidates. Interesting.....
https://synapse.patsnap.com/news-detail/a9d660c9-96a5-3720-8c71-f0babbb48392-boundless-bio-announces-100-million-oversubscribed-series-c-financing-co-led-by-leaps-by-bayer-and-ra-capital-management-to-advance-the-first-ecdna-directed-therapies-ecdtx-for-patients-with-oncogene-amplified-cancer
Good luck, Brighty
OK regarding Boundless Bio and HotblackDesiato's post this is what I have found out. In summary, SRA737 can now also be found as CCT-245737 when searching for Boundless Bio, see the link below:
https://synapse.patsnap.com/drug/32bdb04583b043818d7808672c8fa1c6#research
Of particular interest is this piece of information:
Drug Type
Small molecule drug
Synonyms
PNT-737,
SRA-737,
SRA737
+ [1]
Target
Chk1(Checkpoint kinase 1)
Mechanism
Chk1 inhibitors(Checkpoint kinase 1 inhibitors)
Therapeutic Areas
Neoplasms,
Digestive System Disorders,
Endocrinology and Metabolic Disease
+ [4]
Active Indication
Ovarian Cancer,
Sarcoma,
Small Cell Lung Cancer
+ [13]
Inactive Indication
-
Originator Organization
Sareum Holdings Plc
Sareum Holdings Plc
Active Organization
Sareum Ltd.
Sareum Ltd.
Sierra Oncology, Inc.
Sierra Oncology, Inc.
Institute Of Cancer Research
Institute Of Cancer Research
Inactive Organization
Sareum Holdings Plc
Sareum Holdings Plc
Drug Highest Phase
Phase 2
Good luck, Brighty
ABDX reporting triple digit revenue growth in the first six months. That's good news plus there's a 2nd RNS regarding an update to shareholder concert parties ....
Good luck, Brighty
Exactly and with GSK today paying $1.4 Billion for Aiolos Bio it really does highlight how 10p / 110m mcap is peanuts in our sector. It's also worth adding to your reflections summary the fact that big pharmaceutical companies, as with the GSK deal today, have been paying billions recently for much smaller rivals. e.g. Amgen purchased Horizon Therapeutics for $27.8 Billion, Pfizer acquired Global Blood Therapeutics for $5.4Billion, Pfizer bought Biohaven Pharmaceutical for $11.6 Billion in Cash, Affinivax was bought by GSK for $ 2.10Billion, AstraZeneca acquired CinCor Pharma for $1.8 Billion, Thermo Fisher acquired PeproTech for $1.85 Billion, Pfizer bought Arena for £6.7 Billion, AZ paid 1 billion for KYM Bio and $2 Billion to partner Quell Therapeutics, Eli Lilly acquired Versanis for $1.925 billion, Astellas bought Iveric Bio for $5.9billion, GSK paid £1.6Billion to buy Bellus. i.e. You can see where this could be heading in due course and why 10p a share on positive FDA news is very much attainable before we head much higher with a licencing deal and then a takeover....
Good luck, Brighty
Before dissing the Billion Pound deals in our space don't forget that in addition to the ongoing trials with SDC1801 and plans for SDC1802 we already have a P1 candidate with SRA737. Before Sierra sat on it for a couple of years (in favour of its other lead drug) SRA737 was being hailed as "lethal to cancer cells" and could "have utility as a monotherapy in a range of tumor indications". That's pretty big in our sector. This is why in due course SAR could be a Billion takeover target, especially when you then add SDC1801 and SDC1802 in to the mix. SRA737 might yet blindside many of the doubters on here if our new JV partner in the USA can develop the "lethal to cancer cells" data. How much would that be worth??....
Good luck, Brighty
Neil Elton joins MTEC as CFO from Learning Technologies Group Plc
Starts on 15 January 2024 and will join the Board of Directors on 1 February 2024
An experienced finance professional with more than 18 years' experience as CFO of high-growth, publicly quoted companies. His most recent public company role was CFO at Learning Technologies Group Plc
"create long-term shareholder value":
Neil Elton:
"I look forward to joining Made Tech and to working with Rory and the team to successfully execute the business strategy and create long-term shareholder value."
We could do with a focus on shareholder value.....
Good luck, Brighty
Another £1 Billion + deal in our sector today, with GSK paying $1 billion upfront and up to $400 million in certain success-based regulatory milestone payments for Aiolos Bio. One day this could be SAR.....
Good luck, Brighty
Yes and as the CEO says, the potential demand for zero emission marine vessels is "enormous" & that the "enhanced reliability, performance and compact nature of our novel motor technology will be very appealing to marine operators". Fantastic....
Good luck, Brighty
The RNS today, summary of key points below, would explain that £55,000 buy on Friday...
* N4P has demonstrated via a series of in vitro experiments that Nuvec® can deliver increased transduction efficacy, when complexed with Adeno-Associated virus 8 ("AAV8").
* This follows on from earlier work where the Company showed that Nuvec® increased transduction efficacy of a standard Adenovirus vector.
* Specifically, Nuvec® was mixed with AAV8 carrying a fluorescent green protein gene and used to transduce human-like liver cells (induced pluripotent cell model). When the viral vector was complexed with Nuvec®, transduction efficacy increased 2.5-fold compared to the AAV8 vector when used on a standalone basis. AAV8 was chosen for investigation as this virus is currently being used for products already in clinical development.
* The number of approvals of new gene therapies and the need for appropriate delivery systems have reached unprecedented highs and demand is growing exponentially.
* The AAV vector market alone (AAV based gene therapy and AAV manufacturing) is projected to grow from USD 1.9 billion in 2022 to USD 11.1 billion by 2035.
* For in vivo gene therapy, the Adenovirus (AV) and Adeno-Associated virus (AAV) are acknowledged as the most used delivery vehicles. However relatively high amounts of AV and AAV are needed to be clinically efficient and this appears directly correlated with adverse events in patients such as unwanted immunogenicity and potential safety implications.
CEO Quote:
"Our work shows that Nuvec® has the potential to reduce the amount of AV and AAV needed and thus decrease both the cost of goods and immunogenicity associated with using these viral vectors. We believe this will be a major focus of the pharma/biotech industry as these viral vector delivery systems are further investigated.
"This work is running in parallel to our ongoing oral and dual loading work as well as the Nanogenics' Glaucoma product, an update on which will follow soon."
In a nutshell, yet more encouraging news from N4P....
Good luck, Brighty
Yes, it's a waiting game. N4P is at present anonymous on the investor radar. That needs to change. However, the rapidly changing nature of the vaccine & oncology treatment markets and the significant opportunity that this presents for siRNA delivery is clearly a massive opportunity for N4P. For example:
* The market size for manufacturing viral vectors is currently worth $5.5 billion and is expected to hit $12.8 billion by 2028
* Data has shown that Nuvec is comparable to Roche's Venetoclax and AZ's Gefitinib. That is significant in our sector.
* More news is expected soon, according to the recent N4P briefings.
Once the investment community finally realises what's going on here it really is going to be fascinating to watch the share price rise. So, it is over to Nigel and the team now to finally get the message out there and bang the N4P drum. Who knows but we might even witness your 30p prediction....
Good luck, Brighty
Get them whilst you can at 12p ! The current share price hugely under values MTEC based on FY revenue up 37% to £40.2m, cash of £8.5m, contracted backlog growth of 44%, EBITDA of £1.5m and sales bookings up nearly 40% at £69.9m.
A reminder, MTEC's share price was over 40p last year and just 2 years ago it was 140p a share. A serious share price re-rate could be on the cards here.....
Good luck, Brighty
ABDX will be providing a trading update in the next few days, in which the company will announce that:
* "Revenue for H1 FY23/24 is significantly higher than revenue for H1 FY22/23."
* "We remain highly focused on continuing to grow our revenues and reducing our cash-burn in FY23/24 and beyond".
* "Our ongoing priority is moving the Company to a positive cash flow position based on continued revenue growth and stringent cost control."
Good luck, Brighty
Agreed and it won't be too long before the UK / FCA will have to embrace the NEO bank model. It has to when you bear in mind that NEO banking already has a global market size of 72.47 Billion. Angra Limited with Wellesley at CEO is a first class move…
Good luck, Brighty
Yes, spot on re your HSBC comparison. We are the new kids in town with, as you quite rightly say, "the wallet, the fx, the exchange, 4 stablecoins for the masses & also the bespoke p2p, b2b business angle with bases in Canada, UK, Singapore, HK, Europe/Lithuania, Perth so far". Plus, don't forget the huge revenue potential of 0.2% of each BTC traded on the GS20 Exchange .....
Good luck, Brighty
This is a $50.25 billion sector (2024) & is projected to reach USD $144.48 billion over the next five years. Even if DGI can achieve a miniscule share of the market this will be huge for the company and its share price.
Then factor in the current EV battery replacement price of between $5,000 and $20,000 and DGI's proposition becomes even more compelling and sustainable. The lower environmental impact of sodium and lithium-ion batteries are a game changer in the industry. That's why the Tesla Trio have bought in to DGI.....
https://www.mordorintelligence.com/industry-reports/global-electric-vehicle-battery-market-industry
Good luck, Brighty
Here's a couple of interesting links, below, for long term SAR investors:
* The biopharma industry will continue to see healthy M&A activity in 2024, according to a PwC report, with deals totaling $225 billion to $275 billion.
https://www.biospace.com/article/2024-predictions-for-biotech-m-and-as-/
* And here's more M&A deal activity in our space to excite Sareum shareholders who have a long term investment strategy....
https://www.biospace.com/article/biopharma-closes-2023-with-flurry-of-m-and-a-activity-from-astrazeneca-bms-roche/
Good luck, Brighty
Come on Richard Marsden & the SNG BOD. The link below confirms that Verona is finalising the commercial launch of its drug candidate Ensifentrine, designed to treat COPD. We know SNG001 / Interferon Beta can save lives and that our data is compelling. SNG must speed the process along or on-licence SNG001 ASAP or we are going to be too late to the party....
https://www.biospace.com/article/verona-gets-400m-boost-from-oxford-finance-hercules-capital-for-copd-candidate/
Plus a reminder of what could happen here in due course: https://www.biospace.com/article/biopharma-closes-2023-with-flurry-of-m-and-a-activity-from-astrazeneca-bms-roche/
Good luck, Brighty
I love your "Wake me up at 1p" .... However, I'm not waking until 2p at least ! Which, by the way, could happen sooner than some people on here think. A x10 from today's share price to 2p a share is still only a 200 Million Mcap business. Longer term, I reckon 20p+ a share in 2-3 years time is very possible. Those that are happy to wait a couple of years could be very happy....
https://biz.crast.net/tesla-mastermind-sodium-tech-and-little-known-welsh-car-battery-maker/
https://www.youtube.com/watch?v=fNaqHpqMhlI
Good luck and Happy 2024, Brighty
It's well worth pointing out as we await the anticipated move in to the clinic and then licencing news from HEMO in 2024 that big pharma sign the majority of their licencing deals at the earliest stages, as this data from JP Morgan highlights:
* The largest share of in-license deals into big pharma happens at platform and discovery stages.
* These are often the riskiest but provide the partners substantial support and control over programme development.
* Deals signed at these earliest stages saw median upfront payments of $45 million in 2023, to date.
* Large-cap biopharma (market cap of $50 billion-plus) are still signing $100 million-plus deal upfronts. Median upfront values increased for Platform / Discovery stage programmes as well, reaching $47 million.
Here are some of the biggest licencing deals in 2023:
* Akeso paid $500 million upfront by Summit Therapeutics in 2023 to in-license ivonescimab. Additionally, the partnership outlines a potential deal value of up to USD 4.5 billion.
* Alnylam received an upfront cash payment of USD 310 million from Roche in 2023 to co-develop and co-commercialize Zilebesiran. Additional development, regulatory, and sales milestones could potentially elevate the deal value to USD 2.8 billion.
* Evotec paid $50 Million upfront in 2023 by Bristol Myers Squibb. Tiered royalties on product sales further underscore the financial commitment, resulting in USD 4bn potential deal value.
* Kelun-Biotech paid an upfront $175 Million by Merck in 2023 to co-develop preclinical antibody-drug conjugates. Future development, regulatory, and sales milestone payments, which could total up to USD 9.3 billion.
Source: https://www.jpmorgan.com/content/dam/jpm/commercial-banking/insights/life-sciences/jpmorgan-chase-q3-2023-biopharma-final-ada_v2.pdf
Prevail are onboard with HEMO for a reason......
Good luck, Brighty
Yes and just look at some of the 2023 licencing deals in our sector, below. No reason why AVCT can't be next:
* Alnylam received an upfront cash payment of USD 310 million from Roche in 2023 to co-develop and co-commercialize Zilebesiran. Additional development, regulatory, and sales milestones could potentially elevate the deal value to USD 2.8 billion.
* Evotec paid $50 Million upfront in 2023 by Bristol Myers Squibb. Tiered royalties on product sales further underscore the financial commitment, resulting in USD 4bn potential deal value.
* Akeso paid $500 million upfront by Summit Therapeutics in 2023 to in-license ivonescimab. Additionally, the partnership outlines a potential deal value of up to USD 4.5 billion.
* Kelun-Biotech paid an upfront $175 Million by Merck in 2023 to co-develop preclinical antibody-drug conjugates. Future development, regulatory, and sales milestone payments, which could total up to USD 9.3 billion.
It's got to be a whopping licencing deal soon for AVCT....
Good luck, Brighty